Tiziana Life Sciences (Nasdaq: TSLA / AIM: TILS) Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 million March 12, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, March 12, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announced the pricing of its underwritten follow-on public offering (the “Offering”) of American Depositary Shares (“ADSs”) on the NASDAQ Global Market. Tiziana will issue 3,333,333 ADSs (representing 16,666,665 new ordinary shares…

Tiziana Life Sciences developing TZLS-501 as a potential treatment for Coronavirus patients March 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

Nasdaq and AIM listed Tiziana Life Sciences plc (Nasdaq: TSLA / AIM: TILS) has today announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure. Tiziana, a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, is expediting development of TZLS-501, with Novimmune, SA, a Swiss biotechnology company with whom it entered into a world-wide license for composition-of-matter in 2017.…

Tiziana Life Sciences (Nasdaq: TLSA; AIM: TILS) – TZLS-501 Potential Treatment of Certain Patients Infected with Coronavirus COVID-19 – Posted in: Tiziana Life Sciences (TILS)

New York/London, March 11, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2). Tiziana plans to administer TZLS-501 using a proprietary formulation technology. The Company entered into a world-wide license for composition-of-matter…

Tiziana Life Sciences #TILS – Result of GM, Resolutions Duly Passed February 20, 2020 – Posted in: Tiziana Life Sciences (TILS)

At the General Meeting of the Company held at 10.00 a.m. on 20 February 2020 at the offices of Orrick, Herrington & Sutcliffe (UK) LLP, 107 Cheapside, London, EC2V 6DN, the resolutions to seek additional authorities to issue shares and to disapply pre-emption rights were duly passed. The results of the proxy voting will be available shortly on the Company’s website, www.tizianalifesciences.com. The person who arranged for the release of this announcement was Tiziano Lazaretti,…

Tiziana Life Sciences #TILS Announces Proposed U.S. Public Offering of ADSs February 17, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, February 17, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces the commencement of an underwritten public offering in the United States of American Depositary Shares (“ADSs”), representing ordinary shares of nominal value £0.03 each in the capital of the…

Tiziana Life Sciences #TILS – CEO Gabriele Cerrone Adds To Shareholding February 4, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 4 February 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on the 3 February 2020 it was informed that on that date, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought 5,000 ADSs (each representing 5 Ordinary Shares) at a price of $2.37 per ADS, as set out…

Tiziana Life Sciences #TILS – Notice of General Meeting February 3, 2020 – Posted in: Tiziana Life Sciences (TILS)

Further to the announcement released on 23 January 2020 concerning the filing of a shelf registration document with the SEC to facilitate the raising of additional equity capital, the Company announces that it will hold a General Meeting of the Company at 10.00 a.m. on 20 February 2020 at the offices of Orrick, Herrington & Sutcliffe (UK) LLP, 107 Cheapside, London, EC2V 6DN to seek general authorities to issue shares which would be required in…

Tiziana Life Sciences #TILS – Filing of SEC Form F-3 January 23, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 23 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces the Company has today filed a Form F-3 with the Securities Exchange Commission. An F-3 filing is a shelf registration statement for securities which may enable the Company to potentially conduct a future fundraising (but absent any specific terms at the current time). Contacts:…

Tiziana Life Sciences #TILS Appoints Gregor MacRae to strengthen the Board January 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 21 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, is pleased to announce appointment of Mr. Gregor MacRae to its Board as a Non-executive Director. Mr. Gregor MacRae holds a Law degree (LLB Hons) from the University of Birmingham. He is a qualified Chartered Accountant (ICAEW) and has been a financial and business strategy…

Tiziana Life Sciences #TILS – Exec Chairman Gabriele Cerrone purchases more shares January 14, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London, 14 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on the 13 January 2020 it was informed that on that date, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought 28,500 Ordinary Shares at a price of 43 pence per Ordinary Share, as set out below. The…

« First
Previous
1
...
6
7
8
9
10
11
Next
Last »